Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma (Q45884086)

17 December 2017

title

Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma (English)

1 reference

17 December 2017

1 reference

3

1 reference

17 December 2017

Mauro Provinciali

6

1 reference

17 December 2017

author name string

A Smorlesi

1

1 reference

17 December 2017

F Papalini

2

1 reference

17 December 2017

A Donnini

4

1 reference

17 December 2017

F Re

5

1 reference

17 December 2017

publication date

1 September 2005

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

12

1 reference

17 December 2017

issue

17

1 reference

17 December 2017

page(s)

1324-1332

1 reference

17 December 2017

Vaccination against the HER-2/neu oncogenic protein

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

DNA vaccination against neu reduces breast cancer incidence and metastasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Immunomodulatory and pharmacologic properties of imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Cancer immunotherapy: breaking the barriers to harvest the crop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Immunoprevention and immunotherapy of cancer in ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Cutting Edge: IL-10-producing CD4 T cells mediate tumor rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Specific and nonspecific immunity in the prevention of spontaneous tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Cancer immunoprevention: tracking down persistent tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Cancer vaccines: between the idea and the reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

7 January 2021

Low effectiveness of DNA vaccination against HER-2/neu in ageing

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

7 January 2021

p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

7 January 2021

Optimization of cytotoxic assay by target cell retention of the fluorescent dye carboxyfluorescein diacetate (CFDA) and comparison with conventional 51CR release assay

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

7 January 2021

Calculation of lytic units for the expression of cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1038/SJ.GT.3302559

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302559

1 reference

17 December 2017

Dimensions Publication ID

1051332445

0 references

1 reference

17 December 2017